Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...
Untreated mental health issues, like Treatment-Resistant Depression (TRD), cost U.S. businesses billions annually in lost ...
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...
Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...
Highlights: Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025 Phase 3 COMP006 in TRD is on track for ...
We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth ...
A local psychiatrist is taking a unique approach to treating depression at his Saratoga County practice. Manuel Astruc, M.D. & Associates provides Transcranial Magnetic Stimulation Therapy. It's a non ...
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.
Despite a significant net loss, Compass Pathways PLC (CMPS) secures financing to advance key clinical trials and strengthen its financial position.
Discover how cannabinoid receptor type 1 (CB1) influences resilience to stress and its potential in treating anxiety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results